Prof Nikola Sprigg
Professor of Stroke Medicine
University of Nottingham
DCN Hub, D Floor, South Block
Queen's Medical Centre, Derby Road
Nottingham
NG7 2UH

Email: approvals@hra.nhs.uk
HCRW.approvals@wales.nhs.uk

18 November 2021

Dear Prof Sprigg

HRA and Health and Care Research Wales (HCRW) Approval Letter

Study title:	**Tranexamic acid for Hyperacute Spontaneous Intracerebral Haemorrhage (TICH-3)**
IRAS project ID:	**297457**
EudraCT number:	**2021-001050-62**
Protocol number:	**21022**
REC reference:	**21/EM/0243**
Sponsor	**University of Nottingham**

I am pleased to confirm that **HRA and Health and Care Research Wales (HCRW) Approval** has been given for the above referenced study, on the basis described in the application form, protocol, supporting documentation and any clarifications received. You should not expect to receive anything further relating to this application.

Please now work with participating NHS organisations to confirm capacity and capability, in line with the instructions provided in the "Information to support study set up" section towards the end of this letter.

How should I work with participating NHS/HSC organisations in Northern Ireland and Scotland?
HRA and HCRW Approval does not apply to NHS/HSC organisations within Northern Ireland and Scotland.

If you indicated in your IRAS form that you do have participating organisations in either of these devolved administrations, the final document set and the study wide governance report

(including this letter) have been sent to the coordinating centre of each participating nation. The relevant national coordinating function/s will contact you as appropriate.

Please see IRAS Help for information on working with NHS/HSC organisations in Northern Ireland and Scotland.

How should I work with participating non-NHS organisations?
HRA and HCRW Approval does not apply to non-NHS organisations. You should work with your non-NHS organisations to obtain local agreement in accordance with their procedures.

What are my notification responsibilities during the study?

The standard conditions document "*After Ethical Review – guidance for sponsors and investigators*", issued with your REC favourable opinion, gives detailed guidance on reporting expectations for studies, including:

- Registration of research
- Notifying amendments
- Notifying the end of the study

The HRA website also provides guidance on these topics, and is updated in the light of changes in reporting expectations or procedures.

Who should I contact for further information?
Please do not hesitate to contact me for assistance with this application. My contact details are below.

Your IRAS project ID is **297457**. Please quote this on all correspondence.

Yours sincerely,

Kelly Rowe

Approvals Manager

Email: approvals@hra.nhs.uk

Copy to: *Ms Angela Shone*

List of Documents

The final document set assessed and approved by HRA and HCRW Approval is listed below.

Document	*Version*	*Date*
Covering letter on headed paper [Cover Letter REC]		12 August 2021
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Insurance letter]		20 July 2020
Investigator's brochure / IMP Dossier [IMP label]	1.0	09 August 2021
IRAS Application Form [IRAS_Form_17092021]		17 September 2021
Letter from funder [Funder's Letter]		30 November 2020
Letter from sponsor [Sponsor Letter Signed]		13 August 2021
Non-validated questionnaire [TICH-3_Day_180_follow-up_20211011_v1.0_posta]	1.0	11 October 2021
Other [Amended OID]	1,6	05 October 2021
Other [Amended NCA-TICH-3]		05 October 2021
Other [TICH-3 Consent Process 12.10.2021 figure with tracked changes]	1.0	12 October 2021
Other [Consent Flow Chart]	1.0	09 November 2021
Other [Participant Consent Form with Track Changes]	0.3	03 November 2021
Other [Participant Information Sheet with track changes]	0.3	03 November 2021
Other [Participant Short Information Sheet with track changes]	0.3	02 November 2021
Other [Professional Legal Representative Full Consent Form with track changes]	0.3	03 November 2021
Other [Professional Legal Representative Information Sheet with track changes]	0.4	03 November 2021
Other [Professional Legal Representative Short Information Sheet and Consent with track changes]	0.2	03 November 2021
Other [Relative Legal Representative Full Consent Form with track changes]	0.3	03 November 2021
Other [Relative Legal Representative Full Information Sheet with track changes]	0.4	03 November 2021
Other [Relative Legal Representative Short Information Sheet with track changes]	0.3	03 November 2021
Other [TICH-3 Protocol with track changes]	1.4	03 November 2021
Other [Nikki Sprigg CV]	1.0	09 November 2021
Other [Clinical Trial Authorisation Document]	1.0	03 November 2021
Other [GP Letter]	0.2	03 November 2021
Other [Day 180 Follow Up Questionnaire]	1.0	11 October 2021
Other [Clinical Trials Insurance Certificate]	1.0	26 July 2021
Other [REC Response Letter]	1.1	09 November 2021
Other [Participant Full Consent Form Clean]	1.0	03 November 2021
Other [Participant Information Sheet Clean]	1.0	03 November 2021
Other [Participant Short Information Sheet Clean]	1.0	03 November 2021
Other [Professional Legal Representative Full Consent Form Clean]	1.0	03 November 2021
Other [Professional Legal Representative Information Sheet Clean]	1.0	03 November 2021
Other [Professional Legal Representative Short Information Sheet and Consent Form Clean]	1.0	03 November 2021
Other [Relative Legal Representative Full Consent Form Clean]	1.0	03 November 2021
Other [Relative Legal Representative Information Sheet Clean]	1.0	03 November 2021

Other [Relative Legal Representative Short Information Sheet Clean]	1.0	03 November 2021
Other [TICH-3 Protocol]	1.0	03 November 2021
Schedule of Events or SoECAT [Approved SoECAT]	1.18	12 November 2019
Summary CV for Chief Investigator (CI) [Philip Bath's CV]		30 March 2020
Summary of product characteristics (SmPC) [SmPC TXA]		11 April 2019

IRAS project ID	297457

Information to support study set up

The below provides all parties with information to support the arranging and confirming of capacity and capability with participating NHS organisations in England and Wales. This is intended to be an accurate reflection of the study at the time of issue of this letter.

Types of participating NHS organisation	Expectations related to confirmation of capacity and capability	Agreement to be used	Funding arrangements	Oversight expectations	HR Good Practice Resource Pack expectations
Participating NHS organisations will conduct all study activities as per protocol.	Research activities should not commence at participating NHS organisations in England or Wales prior to their formal confirmation of capacity and capability to deliver the study.	The sponsor intends to use a modified model agreement with participating NHS organisations. The agreement has been modified as follows: • The front page has been amended to include additional identifiers and logo. • Study drug has been redefined in the definitions as Investigational Medicinal Product so that this is not misinterpreted when a drug is used in a non-CTIMP. • Clauses 3.9 – 3.12 have been removed as they can never be applicable when the University is the sponsor. • Clauses 3.13 and 3.14 have been therefore been renumbered 3.8 and 3.9 accordingly. • Clause 6.1 has been amended to include that the CI can provide	Funding has been secured from NIHR HTA, the SoECAT submitted for this study has been authorised by an AcoRD expert.	A PI is expected at participating NHS organisations	It is anticipated that all study activities at site will be conducted by local staff with an existing contractual relationship. No further HR Good Practice arrangements expected.

		permission on behalf of the sponsor. • Clause 16.5 has been amended to state that the agreement can only be executed in counterpart where it is not a CTIMP. • Clause 8.2 has been amended to clarify that financial arrangements will be included in an accompanying payment letter. • Formatting changes have been made to reduce the number of pages. • Schedule 3 has been amended to remove the details for the financial arrangements which are contained in an accompanying payment letter for studies sponsored by the University of Nottingham as the finance signatory differs from the non-commercial agreement signatory. These modifications are within the limits of acceptability and the HRA and HCRW waive the requirement to use an unmodified model agreement. Participating NHS organisations should now determine the acceptability of the modifications and liaise with the sponsor to confirm the content of the agreement. Please note, this waiver does not constitute approval of the agreement, nor does it require NHS organisations to use this agreement.			

Other information to aid study set-up and delivery

This details any other information that may be helpful to sponsors and participating NHS organisations in England and Wales in study set-up.
The applicant has indicated that they intend to apply for inclusion on the NIHR CRN Portfolio. A Substantial amendment will be submitted to change the CI to Prof Nikola Sprigg.